Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19746512 | 1.00 | MEN1 (0.41) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL8740469 | 0.90 | MEN1 (0.36) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL8910074 | 0.88 | MEN1 (0.35) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL9908423 | 0.86 | MEN1 (0.39) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL25233759 | 0.85 | MEN1 (0.41) | MEN1NPC1RAB9AKMT2APOLB | |
| SCHEMBL3332068 | 0.80 | — | — | |
| SCHEMBL3332078 | 0.80 | — | — | |
| SCHEMBL3332075 | 0.80 | — | — | |
| SCHEMBL75491 | 0.80 | — | — | |
| SCHEMBL19604523 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | OSMO LABS PBC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-115516046-A | Coating for food packaging comprising an antimicrobial active ingredient | OMYA国际股份公司 | 2022-12-23 | — | — | CN | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| EP-3681875-A1 | CYCLIC PEPTIDE ANTIBIOTICS | H. Hoffnabb-La Roche Ag (CH) | 2020-07-22 | — | — | EP | disclosed |
| CN-108291096-B | Process for producing pellets comprising surface-reacted calcium carbonate | 欧米亚国际集团 | 2020-06-26 | — | — | CN | disclosed |
| EP-1054881-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2000-11-29 | — | — | EP | disclosed |
| EP-0661271-B1 | AZEPINE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS SIGMA-RECEPTOR LIGANDS | ASAHI CHEMICAL IND (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-6051586-A | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | BAYER CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| WO-1999032475-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999012572-A1 | COMPOUNDS AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETIC RETINOPATHY | UNIVERSITY OF FLORIDA (US) | 1999-03-18 | — | — | WO | disclosed |
| EP-0661271-A1 | AZEPINE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-07-05 | — | — | EP | disclosed |
| EP-0578242-A1 | Process for producing an oligomer | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1994-01-12 | — | — | EP | disclosed |
| US-4895926-A | Hydroxyethylnorbornene compounds and a process for their preparation | EASTMAN KODAK COMPANY (US) | 1990-01-23 | — | — | US | disclosed |
| US-4855395-A | Hydroxyethylnorbornene compounds and a process for their preparation | EASTMAN KODAK COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
| US-4789602-A | Hydroxyethylnorbornene compounds and a process for their preparation | EASTMAN KODAK COMPANY (US) | 1988-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | MEN1 4359/4885NPC1 1580/4885RAB9A 2294/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | MEN1 4359/4885NPC1 1580/4885RAB9A 2294/4885 |
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | CBR1, CBR3, TAS2R1 | MEN1 3787/4885NPC1 1366/4885RAB9A 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.